Table 2.

The combination of I-BET 762 and the rexinoid LG100268 for prevention of lung carcinogenesis

ControlI-BET 762 40 mg/kg dietLG100268 40 mg/kg dietI-BET762+LG268 40 mg each drug/kg diet
Inflated lungs:
 # of mice/group24121212
 # of tumors/group188606257
 # of tumors/lung (% control)7.8 ± 0.5 (100%)5.0 ± 0.5a (63.8%)5.2 ± 0.6a (66%)4.8 ± 0.7a (60.6%)
 # of tumors < 0.5 mm (% of total tumors)5 (2.7%)7a (11.7%)9b (14.5%)13b (22.8%)
 # of tumors > 1 mm (% of total tumors)21 (11.2%)1a (1.7%)6 (9.7%)1 (1.8%)
Slides:
 # of slides/group48242424
 # of tumors/group92223919
 Average # of tumors/slide (% control)1.92 ± 0.25 (100%)0.92 ± 0.15a (47.8%)1.63 ± 0.32 (84.8%)0.79 ± 2a (41.3%)
 Average tumor size, mm3 (% control)0.24 ± 0.09 (100%)0.10 ± 0.02a (39.8%)0.11 ± 0.02a (45.8%)0.10 ± 0.03a (42.5%)
 Average tumor burden, mm3 (% control)0.47 ± 0.19 (100%)0.09 ± 0.02a (19.1%)0.18 ± 0.04 (38.8%)0.08 ± 0.03a (17.5%)
Histopathology:
 Total # LL Grade (% of total tumors)4 (4%)1 (4%)1 (3%)3 (16%)
 Total # LH/HL Grade (% of total tumors)53 (58%)16 (73%)22 (56%)12 (63%)
 Total # HH Grade (% of total tumors)35 (38%)5 (23%)16 (41%)4 (21%)
  • NOTE: The same model was used as Table 1, but a lower concentration of I-BET 762 and a potent rexinoid (LG100268) were tested. The tumor number, size, and histopathology were again assessed in a blinded fashion by two independent investigators. Results are shown as mean ± SEM.

  • aP < 0.05 vs. control.

  • bP < 0.001 vs. control.